Effect of Sodium Metavanadate Supplementation on Lipid and Glucose Metabolism Biomarkers in Type 2 Diabetic Patients
- Author:
Mohammad Afkhami-Ardekani
;
Mahdi Karimi
;
Seid Mohammad Mohammadi
;
Forough Nurani
- Publication Type:Journal Article
- From:
Malaysian Journal of Nutrition
2008;14(1):113-119
- CountryMalaysia
- Language:English
-
Abstract:
Type 2 diabetes mellitus is a chronic, progressive illness that causes considerable morbidity and premature mortality. Vanadium is a trace mineral that has been
claimed to be effective in controlling blood glucose levels in diabetic patients. A randomised placebo-controlled study was conducted to evaluate the effect of
sodium metavanadate on selected biochemical markers in type 2 diabetic patients. Forty patients were enrolled and half of them received 100 mg sodium
metavanadate daily for 6 weeks while the other half were placebo subjects. The mean age of the patients was 53.1 ± 8.5 years. Body mass index (BMI), blood
pressure(BP), fasting blood sugar (FBS), 2-h postprandial glucose, glycated hemoglobin (HbA1C), triglyceride(TG), total cholesterol (TC), low-density
lipoproteins (LDL), high-density lipoproteins (HDL) were determined before the start and at the end of the study. Levels of FBS, HbA1C, TC and LDL in the
diabetic subjects decreased after six weeks on sodium metavanadate, but the differences were not statistically significant on comparing between pre- and posttrial
levels. Based on the results, this study did not find sodium metavanadate of beneficial use as a form of vanadium supplementation among patients with type
2 diabetes.
- Full text:W020150710347434551499.pdf
